Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1299 studies found for:    Open Studies | "Lymphoma"
Show Display Options
Rank Status Study
21 Recruiting A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Condition: Follicular Lymphoma
Interventions: Biological: PF-05280586;   Biological: MabThera®
22 Recruiting Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Rituximab, bendamustine
23 Recruiting A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Condition: B-cell Lymphoma
Interventions: Drug: selinexor;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Oxaliplatin;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Gemcitabine
24 Recruiting A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Citrovorum
25 Recruiting Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
26 Recruiting Phase II Study of TAK228 in Relapsed Lymphoma
Condition: Lymphoma
Interventions: Drug: TAK228;   Other: Blood Sugar Testing
27 Recruiting The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Condition: Non-Hodgkin Lymphoma
28 Recruiting Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
29 Recruiting Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
30 Recruiting Maintenance Lenalidomide in Lymphoma
Condition: Lymphoma
Intervention: Drug: Lenalidomide
31 Recruiting S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
32 Recruiting CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
Condition: Lymphoma
Intervention: Biological: CD19 targeted chimeric antigen receptor T cells
33 Recruiting Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas
Condition: B-cell Lymphomas
Intervention: Genetic: Anti-CD19 CAR T cells
34 Recruiting Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Condition: Mantle-Cell Lymphoma
Interventions: Biological: G-CSF;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Vincristine
35 Recruiting Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab (GA101)
36 Recruiting Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Lenalidomide
37 Recruiting Brazilian Network for Lymphoma Registry
Condition: Lymphoma
Intervention: Other: Observational, non-intervention
38 Recruiting Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: ONC201;   Behavioral: Phone Call
39 Not yet recruiting Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
Condition: LYMPHOMA
Interventions: Drug: Durvalumab;   Drug: Lenali
40 Recruiting Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: G-CSF

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.